Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Intellia Therapeutics Inc NTLA

Healthcare Biotechnology
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:NTLA)

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

GlobeNewswire 8 days ago

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire November 7, 2024

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 5, 2024

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

GlobeNewswire October 31, 2024

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

GlobeNewswire October 24, 2024

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

GlobeNewswire October 10, 2024

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

GlobeNewswire October 7, 2024

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 3, 2024

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

GlobeNewswire October 1, 2024
View More News ››

Opinion & Analysis (NDAQ:NTLA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NTLA)

Intellia Presents Positive Results from the Phase 2 Study of

Breaking News: $NTLA Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene...
whytestocks - October 24, 2024

When (NTLA) Moves Investors should Listen

JUST IN: $NTLA When (NTLA) Moves Investors should Listen2024-10-12 17:54:00 ET Stock Traders Daily has produced this trading report...
whytestocks - October 12, 2024

Intellia Therapeutics, Inc. (NASDAQ:NTLA): Pioneering the Ne

http://beyondspx.com/2024/08/01/intellia-therapeutics-inc-nasdaqntla-pioneering-the-next-generation-of-gene-editing-therapies/
MikeTester - August 2, 2024

REVERSAL TIME

If youre a day trader, you should definitely check out BULLALERTS They send a watchlist covering the top pre-market movers every day...
lebaoxuiyo15 - November 1, 2022

🎥📰Anthony Durkacz on Building a Turnaround at FSD Pharma📣

<< View Post To Watch Video >>
HarryPerkins - November 18, 2021

🎉📣FSD Pharma's Research and Clinical Advisory Board📢

Dr. Eleanor N. Fish, a world-renowned immunologist and cytokine expert, has been appointed to FSD Pharma's Research and Clinical...
HarryPerkins - November 17, 2021
View more Bullboard ››

Regenx Tech Corp.

Regenx Tech Corp.

Regenx Tech Corp. is a cleantech company. The Company is engaged in the development and commercialization of its processing ...
View More »